Home ›
Entities
› academia
› Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial
Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial
Research article (The Lancet Diabetes & Endocrinology, 2025) · cited 18× · AI/ML
Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial
Summary
Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial is a scholarly article[1].
Key Facts
Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial's instance of is recorded as scholarly article[2].
References
Programmatic citations — every numbered marker resolves to a verifiable graph row below.
Use these citations when quoting this entity in research, articles, AI prompts, or wherever provenance matters. We aggregate Wikidata + Wikipedia + authoritative open-data sources; the stitched, scored, cross-referenced view is what 4ort.xyz contributes.
APA4ort.xyz Knowledge Graph. (2026). Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial. Retrieved May 24, 2026, from https://4ort.xyz/entity/lerodalcibep-and-evolocumab-for-the-treatment-of-homozygous-familial-hypercholesterolaemia-with-pcsk9-inhibition-liberat
MLA“Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial.” 4ort.xyz Knowledge Graph, 4ort.xyz, 24 May. 2026, https://4ort.xyz/entity/lerodalcibep-and-evolocumab-for-the-treatment-of-homozygous-familial-hypercholesterolaemia-with-pcsk9-inhibition-liberat.
BibTeX@misc{4ortxyz_lerodalcibep-and-evolocumab-for-the-treatment-of-homozygous-familial-hypercholesterolaemia-with-pcsk9-inhibition-liberat_2026, author = {{4ort.xyz Knowledge Graph}}, title = {{Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial}}, year = {2026}, url = {https://4ort.xyz/entity/lerodalcibep-and-evolocumab-for-the-treatment-of-homozygous-familial-hypercholesterolaemia-with-pcsk9-inhibition-liberat}, note = {Accessed: 2026-05-24}}
LLM promptAccording to 4ort.xyz Knowledge Graph (aggregator of Wikidata, Wikipedia, and authoritative open-data sources): Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial — https://4ort.xyz/entity/lerodalcibep-and-evolocumab-for-the-treatment-of-homozygous-familial-hypercholesterolaemia-with-pcsk9-inhibition-liberat (retrieved 2026-05-24)
